Trisomy 21 Enhances Human Fetal Erythro-megakaryocytic Development

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Sep 25

PMID 18812473

Citations 64

Authors

Stella T Chou

Joanna B Opalinska

Yu Yao

Myriam A Fernandes

Anna Kalota

John S J Brooks

John K Choi

Alan M Gewirtz

Gwenn-ael Danet-Desnoyers

Richard L Nemiroff

Mitchell J Weiss

Affiliations

Soon will be listed here.

Abstract

Children with Down syndrome exhibit 2 related hematopoietic diseases: transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (AMKL). Both exhibit clonal expansion of blasts with biphenotypic erythroid and megakaryocytic features and contain somatic GATA1 mutations. While altered GATA1 inhibits erythro-megakaryocytic development, less is known about how trisomy 21 impacts blood formation, particularly in the human fetus where TMD and AMKL originate. We used in vitro and mouse transplantation assays to study hematopoiesis in trisomy 21 fetal livers with normal GATA1 alleles. Remarkably, trisomy 21 progenitors exhibited enhanced production of erythroid and megakaryocytic cells that proliferated excessively. Our findings indicate that trisomy 21 itself is associated with cell-autonomous expansion of erythro-megakaryocytic progenitors. This may predispose to TMD and AMKL by increasing the pool of cells susceptible to malignant transformation through acquired mutations in GATA1 and other cooperating genes.

Citing Articles

Childhood leukaemia in Down's syndrome primed by blood-cell bias.

Malinge S Nature. 2024; 634(8032):40-42.

PMID: 39322696 DOI: 10.1038/d41586-024-02785-9.

Aberrant stem cell and developmental programs in pediatric leukemia.

Ling R, Cross J, Roy A Front Cell Dev Biol. 2024; 12:1372899.

PMID: 38601080 PMC: 11004259. DOI: 10.3389/fcell.2024.1372899.

Modeling primitive and definitive erythropoiesis with induced pluripotent stem cells.

Pavani G, Klein J, Nations C, Sussman J, Tan K, An H Blood Adv. 2024; 8(6):1449-1463.

PMID: 38290102 PMC: 10955655. DOI: 10.1182/bloodadvances.2023011708.

Down syndrome and leukemia: from basic mechanisms to clinical advances.

Baruchel A, Bourquin J, Crispino J, Cuartero S, Hasle H, Hitzler J Haematologica. 2023; 108(10):2570-2581.

PMID: 37439336 PMC: 10542835. DOI: 10.3324/haematol.2023.283225.

First-Trimester Fetal Hepatic Artery Examination for Adverse Outcome Prediction.

Czuba B, Tousty P, Cnota W, Borowski D, Jagielska A, Dubiel M J Clin Med. 2022; 11(8).

PMID: 35456191 PMC: 9026841. DOI: 10.3390/jcm11082095.

References

Gurbuxani S, Vyas P, Crispino J . Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2003; 103(2):399-406. DOI: 10.1182/blood-2003-05-1556. View

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J . Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003; 102(3):981-6. DOI: 10.1182/blood-2002-11-3599. View

Taub J, Mundschau G, Ge Y, Poulik J, Qureshi F, Jensen T . Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004; 104(5):1588-9. DOI: 10.1182/blood-2004-04-1563. View

Ito E, Kasai M, Hayashi Y, Toki T, Arai K, Yokoyama S . Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome. Br J Haematol. 1995; 90(3):607-14. DOI: 10.1111/j.1365-2141.1995.tb05591.x. View

Hitzler J, Zipursky A . Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005; 5(1):11-20. DOI: 10.1038/nrc1525. View

Crispino J . GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005; 16(1):137-47. DOI: 10.1016/j.semcdb.2004.11.002. View

Langebrake C, Creutzig U, Reinhardt D . Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr. 2005; 217(3):126-34. DOI: 10.1055/s-2005-836510. View

Li Z, Godinho F, Klusmann J, Garriga-Canut M, Yu C, Orkin S . Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):613-9. DOI: 10.1038/ng1566. View

Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G . Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106(5):1565-73. PMC: 1895228. DOI: 10.1182/blood-2005-02-0516. View

10.

Stachura D, Chou S, Weiss M . Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood. 2005; 107(1):87-97. PMC: 1895362. DOI: 10.1182/blood-2005-07-2740. View

11.

Bourquin J, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P . Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A. 2006; 103(9):3339-44. PMC: 1413912. DOI: 10.1073/pnas.0511150103. View

12.

Massey G, Zipursky A, Chang M, Doyle J, Nasim S, Taub J . A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. 2006; 107(12):4606-13. DOI: 10.1182/blood-2005-06-2448. View

13.

Ghinassi B, Sanchez M, Martelli F, Amabile G, Vannucchi A, Migliaccio G . The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor. Blood. 2006; 109(4):1460-71. PMC: 1794062. DOI: 10.1182/blood-2006-07-030726. View

14.

Pine S, Guo Q, Yin C, Jayabose S, Druschel C, Sandoval C . Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood. 2007; 110(6):2128-31. DOI: 10.1182/blood-2007-01-069542. View

15.

Lange B . The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000; 110(3):512-24. DOI: 10.1046/j.1365-2141.2000.02027.x. View

16.

Wechsler J, Greene M, McDevitt M, Anastasi J, Karp J, Le Beau M . Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32(1):148-52. DOI: 10.1038/ng955. View

17.

Manz M, Miyamoto T, Akashi K, Weissman I . Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A. 2002; 99(18):11872-7. PMC: 129361. DOI: 10.1073/pnas.172384399. View

18.

Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, OMarcaigh A . Natural history of GATA1 mutations in Down syndrome. Blood. 2003; 103(7):2480-9. DOI: 10.1182/blood-2003-10-3383. View